News Lilly eyes earlier use of blood cancer drug Jaypirca Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.
News Lilly raises stakes in Novartis battle with Verzenio data Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.
News Nykode changes tack after Roche exits partnership Hit by the loss of a partnership with Roche's Genentech unit last year, Norway's Nykode has narrowed its R&D focus.
News Gilead buys in vivo cell therapy firm Interius for $350m Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.
News NICE backs bladder cancer duo that can double survival A new treatment regimen for advanced bladder cancer combining MSD's Keytruda with Astellas' Padcev has been given the green light for NHS use.
News Merck unit gets first EU nod for a desmoid tumour treatment Merck unit SpringWorks has claimed EU approval for Ogsiveo, becoming the first approved therapy for desmoid tumours in Europe.
Patients Delivering the right behavioural ingredients for the moment,... Lirio's Dr Amy Bucher discusses the risks of the declining trust in healthcare institutions from a behavioural science perspective.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.